Grifols SA, Barcelona (GRFS) Upgraded at HSBC

HSBC upgraded shares of Grifols SA, Barcelona (NASDAQ:GRFS) from a reduce rating to a hold rating in a research note issued to investors on Wednesday morning.

Several other research analysts have also issued reports on the stock. Morgan Stanley dropped their price target on shares of Grifols SA, Barcelona from $23.00 to $22.00 and set an underweight rating for the company in a research report on Thursday, March 1st. BidaskClub lowered shares of Grifols SA, Barcelona from a hold rating to a sell rating in a research report on Wednesday, February 28th. ValuEngine raised shares of Grifols SA, Barcelona from a hold rating to a buy rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Grifols SA, Barcelona from a sell rating to a hold rating in a research report on Thursday, January 4th. Finally, UBS lowered shares of Grifols SA, Barcelona from an outperform rating to a market perform rating in a research report on Friday, November 24th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $23.00.

How to Become a New Pot Stock Millionaire

Shares of Grifols SA, Barcelona (GRFS) opened at $21.25 on Wednesday. Grifols SA, Barcelona has a fifty-two week low of $17.28 and a fifty-two week high of $25.18. The company has a current ratio of 3.01, a quick ratio of 1.35 and a debt-to-equity ratio of 1.62. The company has a market cap of $14,619.24, a price-to-earnings ratio of 22.85, a PEG ratio of 1.36 and a beta of 1.18.

A number of institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. grew its stake in Grifols SA, Barcelona by 6.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 180,757 shares of the biotechnology company’s stock worth $4,143,000 after buying an additional 10,937 shares during the last quarter. William Blair Investment Management LLC grew its stake in Grifols SA, Barcelona by 26.6% during the fourth quarter. William Blair Investment Management LLC now owns 200,335 shares of the biotechnology company’s stock worth $4,592,000 after buying an additional 42,107 shares during the last quarter. Two Sigma Investments LP grew its stake in Grifols SA, Barcelona by 26.6% during the fourth quarter. Two Sigma Investments LP now owns 463,606 shares of the biotechnology company’s stock worth $10,626,000 after buying an additional 97,505 shares during the last quarter. Two Sigma Advisers LP grew its stake in Grifols SA, Barcelona by 252.1% during the fourth quarter. Two Sigma Advisers LP now owns 214,100 shares of the biotechnology company’s stock worth $4,907,000 after buying an additional 153,300 shares during the last quarter. Finally, Jefferies Group LLC bought a new stake in Grifols SA, Barcelona during the fourth quarter worth about $1,393,000. 22.26% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://transcriptdaily.com/2018/03/17/grifols-sa-barcelona-grfs-upgraded-at-hsbc.html.

About Grifols SA, Barcelona

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Analyst Recommendations for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply